DJIA 16,643.01 -11.76 -0.07%
NASDAQ 4,828.33 15.62 0.32%
S&P 500 1,988.87 1.21 0.06%
market minute promo

company name or ticker
Company Photos
(Click to zoom)

3 Battleground Biotech Stocks I Would Avoid at All Costs

Arena Pharmaceuticals, Amarin Corp., and Keryx Biopharmaceuticals each have relatively new drugs that once captured the market's imagination. With their real world success in doubt, though, investors might be wise to jump ship now.

Arena Pharmaceuticals (ARNA) Rises: Stock Adds 5.7% in Session

Orexigen: Contrave Wins Another Sales Week - Don't Bank On Impressive Numbers

Vivus Hovers Near 52-Week Lows - Qsymia Sales Not Helping

Bull Or Bear? Biotech's Post-Earnings Buys and Sells

The breakdown on which companies' numbers are easiest to swallow.

The 3 Most Disappointing Drug Launches of All Time

Treatments with huge promise don't always pan out the way you'd expect.

Orexigen- Contrave Sales Win The Week But Still Flatter Than Needed

Arena - Belviq Sales Dip Again. We Have Seen The Peak In 2015

Arena's Smoking Cessation Opportunity

Arena Pharmaceuticals' Belviq Sales Are Better Than They Appear (But They're Still Not Great)

Declining quarter-over-quarter sales look bad, but investors needn't freak out.
See More Articles...